$NUVB

Nuvation Bio (NUVB) reported Q2 call highlights for IBTROZI in ROS1-positive lung cancer, citing TRUST-I results in TKI-naive patients with a 90% objective response rate and 50-month median response duration and progression-free survival. The company said first-line ROS1 TKI use rose nearly 20% through May 2026. It also updated safusidenib Phase II J201 (52% ORR, 79% 36-month PFS) and outlined Phase III/G307 and G209 studies. Cash was $661M after a June convertible notes offering.

NuVasive (NUVB) reported Q2 2026 results on Aug. 6. The company posted EPS of -$0.15, versus -$0.19 expected, and revenue of $31.69 million versus $27.49 million expected. The article also cites recent insider trades and hedge fund position changes, plus a median analyst price target of $13.0.

Nuvation Bio Inc. (NUVB) reported Q2 revenue of $31.7 million, above a FactSet estimate of $27.0 million, according to the earnings flash. The stock was shown around $6.33 per share, down 0.63% on the day and down 28.91% year to date.

Nuvation Bio Inc. (NUVB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d261840dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in net product revenue for IBTROZI ® (taletrectini

Nuvation Bio Inc. (NYSE: NUVB) reported Q2 2026 revenue of $31.7 million, including $23.2 million net product revenue for IBTROZI (taletrectinib). The company said IBTROZI had 25% QoQ growth, with ~85% of ~160 new starts TKI-naïve. Nuvation also cited positive updated Phase 2 long-term data for safusidenib, and reported $661.0 million cash and $36.5 million convertible-note proceeds in July 2026.

Nuvation Bio (NUVB) reported $31.7M total revenue for the quarter and $114.9M for the six months ended June 30, 2026, driven by IBTROZI net product revenue and collaboration and license income, including about $58.7M upfront from Eisai. The company posted a ~$57.4M six-month net loss and ended with $661.0M cash and securities after issuing $250M 0.75% convertible notes.

Nuvation Bio (NUVB) shares fell as investors weighed dilution concerns tied to the company’s upsized $287.5 million convertible senior notes offering. The move also reflected profit-taking and caution ahead of its Q2 2026 results on Aug. 6. The article cites technical support tests after a recent rally on clinical data.

Zacks says Nuvation Bio (NUVB) is expected to report a quarterly loss of $0.15 per share for the quarter ended June 2026, with revenue of $27.12 million. The consensus calls for year-over-year EPS improvement (+11.8%) and revenue growth (+461.5%). Zacks estimates an Earnings ESP of +10.35% and a Zacks Rank of #2 ahead of an Aug. 6 release.

Nuvation Bio (NUVB) shares rose after the company reported updated long-term Phase 2 data for safusidenib in grade 2 IDH1-mutant glioma. RBC Capital analyst Leonid Timashev said the results support safusidenib’s competitive profile versus vorasidenib and cited a potential $3B+ peak market. RBC kept an Outperform rating and $19 price target.

Nuvation Bio (NYSE:NUVB) shares rose about 7% after the company reported updated Phase 2 data for safusidenib and plans to expand its clinical program. It cited a 52% confirmed objective response rate and 79% 36-month progression-free survival in grade 2 IDH1-mutant glioma. Nuvation plans a pivotal Phase 3 outside the U.S. (~140 patients) and a U.S. Phase 2 after vorasidenib progression (up to 40).